A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503802-35-00

Acronym

VP-VLY-686-3304

Enrollment

Registered

2024-12-03

Start date

2023-11-29

Completion date

Unknown

Last updated

2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic or diabetic gastroparesis with moderate to severe nausea.

Brief summary

To evaluate dosing of tradipitant on standard measures of subject safety by assessing adverse events (AEs) including suicidal ideation or behavior, changes in vital signs, clinical laboratory evaluations, electrocardiograms (ECGs) and physical exam findings during treatment.

Interventions

DRUGTradipitant

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To evaluate dosing of tradipitant on standard measures of subject safety by assessing adverse events (AEs) including suicidal ideation or behavior, changes in vital signs, clinical laboratory evaluations, electrocardiograms (ECGs) and physical exam findings during treatment.	—

Countries

Belgium, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026